[artículo] 
inThe Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 4 (Abril) . - pp. 556-563

Título :	Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide : a retrospective analysis of 134 patients with mild cognitive impairment
Tipo de documento:	texto impreso
Autores:	Katharina Buerger, Autor ; Olga Uspenskaya, Autor ; Oliver Hartmann, Autor
Fecha de publicación:	2022
Artículo en la página:	pp. 556-563
Idioma :	Inglés (eng) Idioma original : Inglés (eng)
Palabras clave:	Enfermedad de Alzheimer, Biomarcadores, Trastornos cognitivos, Enfermedad progresiva.
Resumen:	Development of biomarkers for early detection of Alzheimer's disease (AD) is a major clinical research goal. On the basis of the hypothesis that cardiovascular risk factors contribute to the pathogenesis of AD, we investigated whether the cardiovascular risk markers midregional proadrenomedullin (MR-proADM) and midregional proatrial natriuretic peptide (MR-proANP) predict a major clinical milestone, ie, conversion from predementia mild cognitive impairment (MCI) to manifest AD.
Link:	./index.php?lvl=notice_display&id=27984

[artículo] Prediction of Alzheimer's disease using midregional proadrenomedullin and midregional proatrial natriuretic peptide : a retrospective analysis of 134 patients with mild cognitive impairment [texto impreso] / Katharina Buerger, Autor ; Olga Uspenskaya, Autor ; Oliver Hartmann, Autor . - 2022 . - pp. 556-563.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in The Journal of Clinical Psychiatry > Año 2011 - Vol.72 - No. 4 (Abril) . - pp. 556-563

Palabras clave:	Enfermedad de Alzheimer, Biomarcadores, Trastornos cognitivos, Enfermedad progresiva.
Resumen:	Development of biomarkers for early detection of Alzheimer's disease (AD) is a major clinical research goal. On the basis of the hypothesis that cardiovascular risk factors contribute to the pathogenesis of AD, we investigated whether the cardiovascular risk markers midregional proadrenomedullin (MR-proADM) and midregional proatrial natriuretic peptide (MR-proANP) predict a major clinical milestone, ie, conversion from predementia mild cognitive impairment (MCI) to manifest AD.
Link:	./index.php?lvl=notice_display&id=27984